Table 4.
Baseline patient demographics, clinical and laboratory data according to ADD2 (β-adducin) genotype
| Variable | C1797C (217) | 1797T (111) | p |
|---|---|---|---|
| Mean (range) ± SEM | Mean (range) ± SEM | ||
| Age at presentation (years) | 31.5 (16–77) ± 0.95 | 31.6 (16–72) ± 1.31 | n.s. |
| Age at biopsy (years) | 34.9 (16–77) ± 0.99 | 34.4 (16–72) ± 1.33 | n.s. |
| Males (% men) | 168 (77%) | 79 (71%) | n.s. |
| Hypertensive (%) | 99 (46%) | 59 (53%) | n.s. |
| Antihypertensive treatment (%) | 94 (43%) | 58 (52%) | n.s. |
| Macrohematuria (%) | 102 (47%) | 41 (37%) | n.s. |
| Body weight (kg) | 70.9 ± 0.72 | 68.9 ± 1.00 | n.s. |
| Height (cm) | 169.4 ± 0.53 | 168.8 ± 0.80 | n.s. |
| Body mass index (kg/m2) | 24.5 ± 0.22 | 23.9 ± 0.27 | n.s. |
| Serum creatinine (mg/dl) | 1.48 ± 0.07 | 1.56 ± 0.16 | n.s. |
| Creatinine clearance (ml/min)a | 82.2 ± 2.51 | 76.9 ± 3.02 | n.s. |
| SBP (mmHg) | 134.8 ± 1.12 | 139.5 ± 2.01 | 0.041 |
| DBP (mmHg) | 86.6 ± 0.78 | 89.3 ± 1.22 | 0.054 |
| Urinary protein excretion (g/24 h) | 1.38 ± 0.09 | 1.63 ± 0.13 | n.s. |
| Follow-up from presentation (years) | 11.4 (4–23) ± 0.34 | 11.3 (4–21) ± 0.58 | n.s. |
| Follow-up from biopsy (years) | 8.4 (4–19) ± 0.24 | 8.6 (4–19) ± 0.49 | n.s. |
| Renal function loss (ml/min year) | −4.77 ± 0.41 | −6.82 ± 0.92 | 0.043 |
If not otherwise indicated, reported data are the ones collected at the time of renal biopsy. Presentation means the first recorded/reported episode of macrohematuria or microhematuria/proteinuria at urinalysis
aComputed with Cockcroft–Gault formula [24]